Instrument Inactif

Communiqués Corcept Therapeutics Nasdaq

Actions

Produits pharmaceutiques

Communiqués

06/06	Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®	BU
29/05	Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure	BU
27/05	Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome	BU
30/04	Corcept: Q1 Earnings Snapshot	AQ
30/04	Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis	BU
30/04	Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update	BU
23/04	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call	BU
22/04	Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026	AQ
21/04	Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026	BU
18/04	Corcept 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT	BU
13/04	Corcept présente les données complètes de l'essai pivot ROSELLA dans le cadre d'une présentation de dernière minute au congrès de la SGO, avec une publication simultanée dans The Lancet : Lifyorli™ (rélacorilant) plus nab-paclitaxel améliore la…	BU
10/04	Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer	BU
04/04	Corcept Therapeutics Incorporated Class Action Reminder – Robbins LLP Encourages CORT Stockholders to Contact the Firm for Information About Their Rights	BU
30/03	Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session	AQ
28/03	Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session	BU
25/03	FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer	BU
16/03	Corcept Therapeutics Incorporated Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights – CORT	AQ
13/03	CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss	AQ
11/03	Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses	AQ
11/03	Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC	AQ
10/03	Class Action Lawsuit Filed on Behalf of Corcept Therapeutics Incorporated (CORT) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm	AQ
09/03	Contact Levi & Korsinsky by April 21, 2026 Deadline to Join Class Action Against Corcept Therapeutics Incorporated(CORT)	AQ
06/03	Class Action Filed Against Corcept Therapeutics Incorporated (CORT) Seeking Recovery for Investors – Contact The Gross Law Firm	AQ
04/03	Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline	AQ
02/03	Class Action Filed Against Corcept Therapeutics Incorporated (CORT) Seeking Recovery for Investors – Contact Levi & Korsinsky	AQ